Cargando…

Systemic inflammation in acute cardiorenal syndrome: an observational pilot study

AIMS: Acute cardiorenal syndrome (CRS) with and without consideration of the volume state was assessed with regard to inflammatory parameters. METHODS AND RESULTS: Blood samples from patients with acute CRS (Ronco type 1 or 3, Group 1, n = 15), end‐stage renal disease (Group 2, n = 12), hypertension...

Descripción completa

Detalles Bibliográficos
Autores principales: Linhart, Christoph, Ulrich, Christof, Greinert, Daniel, Dambeck, Stefanie, Wienke, Andreas, Girndt, Matthias, Pliquett, Rainer U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165938/
https://www.ncbi.nlm.nih.gov/pubmed/30015388
http://dx.doi.org/10.1002/ehf2.12327
_version_ 1783359937617854464
author Linhart, Christoph
Ulrich, Christof
Greinert, Daniel
Dambeck, Stefanie
Wienke, Andreas
Girndt, Matthias
Pliquett, Rainer U.
author_facet Linhart, Christoph
Ulrich, Christof
Greinert, Daniel
Dambeck, Stefanie
Wienke, Andreas
Girndt, Matthias
Pliquett, Rainer U.
author_sort Linhart, Christoph
collection PubMed
description AIMS: Acute cardiorenal syndrome (CRS) with and without consideration of the volume state was assessed with regard to inflammatory parameters. METHODS AND RESULTS: Blood samples from patients with acute CRS (Ronco type 1 or 3, Group 1, n = 15), end‐stage renal disease (Group 2, n = 12), hypertension (Group 3, n = 15), and, in a second cohort, with acute CRS and hypervolemia (Group 4, n = 9) and hypertension (Group 5, n = 10) were analysed with regard to lipopolysaccharide‐binding protein (LBP), interleukins (ILs), and monocyte function (flow cytometry) both on admission (all groups) and on discharge (Groups 1 and 4). By discharge, one Group 1 patient died. LBP (ANOVA for Groups 1–3: P = 0.001) and IL‐6 (Kruskal–Wallis for Groups 1–3: P < 0.0001) were higher in Group 1 (LBP: 11.7 ± 2.0 μg/mL; IL‐6: 15.0 ± 6.1 pg/mL) and in Group 2 (LBP: 10.4 ± 1.4 μg/mL; IL‐6: 14.6 ± 3.8 pg/mL) than in Group 3 (LBP: 5.8 ± 0.4 μg/mL; IL‐6: 1.8 ± 0.4 pg/mL). In a direct comparison, the proportion of activated monocytes (CD14 and CD16 positive) was higher in Group 1 (6.9% ± 0.7%) vs. Group 3 (5.1% ± 0.6%; P = 0.018). Group 4 patients had higher IL‐6 plasma levels (34.2 ± 10.1 pg/mL) than Group 1 patients (15.0 ± 6.1 pg/mL; P = 0.03). All other findings obtained in CRS groups (Groups 1 and 4) were comparable. CONCLUSIONS: In acute CRS, a state of systemic inflammation was found, which is comparable with the end‐stage renal disease situation. In comparison with hypertensive controls, a monocytic activation was found in acute CRS regardless of volume state.
format Online
Article
Text
id pubmed-6165938
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61659382018-10-04 Systemic inflammation in acute cardiorenal syndrome: an observational pilot study Linhart, Christoph Ulrich, Christof Greinert, Daniel Dambeck, Stefanie Wienke, Andreas Girndt, Matthias Pliquett, Rainer U. ESC Heart Fail Original Research Articles AIMS: Acute cardiorenal syndrome (CRS) with and without consideration of the volume state was assessed with regard to inflammatory parameters. METHODS AND RESULTS: Blood samples from patients with acute CRS (Ronco type 1 or 3, Group 1, n = 15), end‐stage renal disease (Group 2, n = 12), hypertension (Group 3, n = 15), and, in a second cohort, with acute CRS and hypervolemia (Group 4, n = 9) and hypertension (Group 5, n = 10) were analysed with regard to lipopolysaccharide‐binding protein (LBP), interleukins (ILs), and monocyte function (flow cytometry) both on admission (all groups) and on discharge (Groups 1 and 4). By discharge, one Group 1 patient died. LBP (ANOVA for Groups 1–3: P = 0.001) and IL‐6 (Kruskal–Wallis for Groups 1–3: P < 0.0001) were higher in Group 1 (LBP: 11.7 ± 2.0 μg/mL; IL‐6: 15.0 ± 6.1 pg/mL) and in Group 2 (LBP: 10.4 ± 1.4 μg/mL; IL‐6: 14.6 ± 3.8 pg/mL) than in Group 3 (LBP: 5.8 ± 0.4 μg/mL; IL‐6: 1.8 ± 0.4 pg/mL). In a direct comparison, the proportion of activated monocytes (CD14 and CD16 positive) was higher in Group 1 (6.9% ± 0.7%) vs. Group 3 (5.1% ± 0.6%; P = 0.018). Group 4 patients had higher IL‐6 plasma levels (34.2 ± 10.1 pg/mL) than Group 1 patients (15.0 ± 6.1 pg/mL; P = 0.03). All other findings obtained in CRS groups (Groups 1 and 4) were comparable. CONCLUSIONS: In acute CRS, a state of systemic inflammation was found, which is comparable with the end‐stage renal disease situation. In comparison with hypertensive controls, a monocytic activation was found in acute CRS regardless of volume state. John Wiley and Sons Inc. 2018-07-17 /pmc/articles/PMC6165938/ /pubmed/30015388 http://dx.doi.org/10.1002/ehf2.12327 Text en © 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research Articles
Linhart, Christoph
Ulrich, Christof
Greinert, Daniel
Dambeck, Stefanie
Wienke, Andreas
Girndt, Matthias
Pliquett, Rainer U.
Systemic inflammation in acute cardiorenal syndrome: an observational pilot study
title Systemic inflammation in acute cardiorenal syndrome: an observational pilot study
title_full Systemic inflammation in acute cardiorenal syndrome: an observational pilot study
title_fullStr Systemic inflammation in acute cardiorenal syndrome: an observational pilot study
title_full_unstemmed Systemic inflammation in acute cardiorenal syndrome: an observational pilot study
title_short Systemic inflammation in acute cardiorenal syndrome: an observational pilot study
title_sort systemic inflammation in acute cardiorenal syndrome: an observational pilot study
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165938/
https://www.ncbi.nlm.nih.gov/pubmed/30015388
http://dx.doi.org/10.1002/ehf2.12327
work_keys_str_mv AT linhartchristoph systemicinflammationinacutecardiorenalsyndromeanobservationalpilotstudy
AT ulrichchristof systemicinflammationinacutecardiorenalsyndromeanobservationalpilotstudy
AT greinertdaniel systemicinflammationinacutecardiorenalsyndromeanobservationalpilotstudy
AT dambeckstefanie systemicinflammationinacutecardiorenalsyndromeanobservationalpilotstudy
AT wienkeandreas systemicinflammationinacutecardiorenalsyndromeanobservationalpilotstudy
AT girndtmatthias systemicinflammationinacutecardiorenalsyndromeanobservationalpilotstudy
AT pliquettraineru systemicinflammationinacutecardiorenalsyndromeanobservationalpilotstudy